IP Library Granted Patent US 8,288,434
Granted Patent B2
US 8,288,434 · App. 12/455,525 · Granted Oct 16, 2012

Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,288,434
App. No.
12/455,525
Granted
Oct 16, 2012
Kind
B2
Abstract

An aqueous formulation for topical application to the skin comprising water, a water-miscible organic solvent, and benzoyl peroxide, wherein the concentration of the organic solvent is sufficient to provide a stable suspension of benzoyl peroxide in the aqueous formulation without the inclusion of a surfactant in the formulation, wherein the ratio of concentrations of water and organic solvent in the formulation is sufficient to maintain the benzoyl peroxide in saturated solubility in the formulation following application to the skin, and wherein the concentration of benzoyl peroxide in the formulation is less than 5.0% and at least 1.0% w/w. The formulation may further contain a chemical compound in addition to benzoyl peroxide that is effective in the treatment of acne. The aqueous formulations of the invention are useful in the treatment of acne and acne rosacea.

Claims (60)

1. An aqueous formulation for topical application to the skin comprising water, a water-miscible organic solvent, and benzoyl peroxide, wherein the concentration of the organic solvent is sufficient to provide a stable suspension of benzoyl peroxide in the aqueous formulation without the inclusion of a surfactant in the formulation, wherein the combined concentration of water and the organic solvent is sufficient to provide a suspension of a benzoyl peroxide in a saturated solution of benzoyl peroxide, and wherein the concentration of benzoyl peroxide in the formulation is less than 5.0% and at least 1.0% w/w.

2. The aqueous formulation of claim 1 wherein the concentration of benzoyl peroxide is between 2.0% and 3.5% w/w.

3. The aqueous formulation of claim 2 wherein the concentration of benzoyl peroxide is about 2.5% w/w.

4. The aqueous formulation of claim 1 wherein the organic solvent is a polyol.

5. The aqueous formulation of claim 4 wherein the polyol is propylene glycol.

6. The aqueous formulation of claim 1 wherein the concentration of the organic solvent is lower than that which will dissolve all of the benzoyl peroxide in the formulation following the removal of all of the water from the formulation.

7. The aqueous formulation of claim 1 wherein the concentration of the organic solvent is 1 to 4 times the concentration of the benzoyl peroxide in the formulation.

8. The aqueous formulation of claim 1 wherein the ratio of water to organic solvent in the formulation is at least 7:1.

9. The aqueous formulation of claim 8 wherein the ratio is at least 10:1.

10. The aqueous formulation of claim 9 wherein the ratio is at least 20:1.

11. The aqueous formulation of claim 1 which is free of surfactant.

12. The aqueous formulation of claim 1 which contains a surfactant.

13. The aqueous formulation of claim 1 which further comprises a water-dispersible gelling agent.

14. The aqueous formulation of claim 1 which further comprises, in addition to benzoyl peroxide, a chemical compound that is effective in the treatment of acne.

15. The aqueous formulation of claim 14 wherein the chemical compound is soluble in water.

16. The aqueous formulation of claim 14 wherein the chemical compound is an antibiotic.

17. The aqueous formulation of claim 16 wherein the antibiotic is a member of the macrolide or lincomycin families of antibiotics.

18. The aqueous formulation of claim 17 wherein the antibiotic is clindamycin.

19. A method for treating acne comprising applying to affected areas of skin an aqueous formulation for topical application to the skin comprising water, a water-miscible organic solvent, and benzoyl peroxide, wherein the concentration of the organic solvent is sufficient to provide a stable suspension of benzoyl peroxide in the aqueous formulation without the inclusion of a surfactant in the formulation, wherein the ratio of concentrations of water and organic solvent in the formulation is sufficient to maintain the suspension of benzoyl peroxide in a saturated solution of benzoyl peroxide in the formulation following application to the skin, and wherein the concentration of benzoyl peroxide in the formulation is less than 5.0% and at least 1.0% w/w for a time sufficient to ameliorate the signs and/or symptoms of acne.

20. The method of claim 19 wherein the concentration of benzoyl peroxide in the aqueous formulation is between 2.0% and 3.5% w/w.

21. The method of claim 20 wherein the concentration of benzoyl peroxide is about 2.5% w/w.

22. The method of claim 19 wherein the organic solvent is a polyol.

23. The method of claim 22 wherein the polyol is propylene glycol.

24. The method of claim 19 wherein the concentration of the organic solvent is lower than that which will dissolve all of the benzoyl peroxide in the formulation following the removal of all of the water from the formulation.

25. The method of claim 19 wherein the concentration of the organic solvent is 1 to 4 times the concentration of the benzoyl peroxide in the formulation.

26. The method of claim 19 wherein the ratio of water to organic solvent in the formulation is at least 7:1.

27. The method of claim 26 wherein the ratio is at least 10:1.

28. The method of claim 27 wherein the ratio is at least 20:1.

29. The method of claim 19 wherein the aqueous formulation is free of surfactant.

30. The method of claim 19 wherein the aqueous formulation contains a surfactant.

31. The method of claim 19 wherein the formulation further comprises a water-dispersible gelling agent.

32. The method of claim 19 wherein the formulation further comprises, in addition to benzoyl peroxide, a chemical compound that is effective in the treatment of acne.

33. The method of claim 32 wherein the chemical compound is soluble in water.

34. The method of claim 32 wherein the chemical compound is an antibiotic.

35. The method of claim 34 wherein the antibiotic is a member of the macrolide or lincomycin families of antibiotics.

36. The method of claim 35 wherein the antibiotic is clindamycin.

37. The aqueous formulation of claim 1 wherein the concentration of the organic solvent is 1 to 4 times the concentration of the benzoyl peroxide in the formulation, wherein the ratio by weight of water to organic solvent in the formulation is at least 7:1, and wherein the concentration of benzoyl peroxide in the formulation is between 1.0% and 3.5% w/w.

38. The aqueous formulation of claim 37 wherein the concentration of benzoyl peroxide in the formulation is about 2.5%.

39. The aqueous formulation of claim 16 wherein the antibiotic is azithromycin.

40. The aqueous formulation of claim 14 wherein the chemical compound is a retinoid.

41. An aqueous formulation for topical application to the skin comprising water, a water-miscible organic solvent, and benzoyl peroxide, wherein the concentration of the organic solvent is sufficient to provide a stable suspension of benzoyl peroxide in the aqueous formulation without the inclusion of a surfactant in the formulation, wherein the combined concentration of water and the organic solvent is sufficient to provide a uniform suspension and a saturated solution of benzoyl peroxide with a dissolved concentration of benzoyl peroxide that is higher than when dissolved in water without the organic solvent, and wherein the concentration of benzoyl peroxide in the formulation is less than 5.0% and at least 1.0% w/w.

42. The aqueous formulation of claim 41 wherein the concentration of benzoyl peroxide is between 2.0% and 3.5% w/w.

43. The aqueous formulation of claim 42 wherein the concentration of benzoyl peroxide is about 2.5% w/w.

44. The aqueous formulation of claim 41 wherein the organic solvent is a polyol.

45. The aqueous formulation of claim 44 wherein the polyol is propylene glycol.

46. The aqueous formulation of claim 41 wherein the concentration of the organic solvent is lower than that which will dissolve all of the benzoyl peroxide in the formulation following the removal of all of the water from the formulation.

47. The aqueous formulation of claim 41 wherein the concentration of the organic solvent is 1 to 4 times the concentration of the benzoyl peroxide in the formulation.

48. The aqueous formulation of claim 41 wherein the ratio of water to organic solvent in the formulation is at least 7:1.

49. The aqueous formulation of claim 48 wherein the ratio is at least 10:1.

50. The aqueous formulation of claim 49 wherein the ratio is at least 20:1.

51. The aqueous formulation of claim 41 which is free of surfactant.

52. The aqueous formulation of claim 41 which contains a surfactant.

53. The aqueous formulation of claim 41 which further comprises a water-dispersible gelling agent.

54. The aqueous formulation of claim 41 which further comprises, in addition to benzoyl peroxide, a chemical compound that is effective in the treatment of acne.

55. The aqueous formulation of claim 54 wherein the chemical compound is soluble in water.

56. The aqueous formulation of claim 54 wherein the chemical compound is an antibiotic.

57. The aqueous formulation of claim 55 wherein the antibiotic is a member of the macrolide or lincomycin families of antibiotics.

58. The aqueous formulation of claim 57 wherein the antibiotic is clindamycin.

59. The aqueous formulation of claim 56 wherein the antibiotic is azithromycin.

60. The aqueous formulation of claim 54 wherein the chemical compound is a retinoid.

Assignments (23)
U.S. PATENT SECURITY AGREEMENT Recorded Nov 25, 2025
From: BAUSCH HEALTH IRELAND LIMITED
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 073715/0375 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 073637/0001 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
Reel/Frame 073637/0126 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMA POLAND SPOLKA Z ORGANICZONA ODPOWIEDZIALNOSCIA; VALEANT SP. Z.O.O.
Reel/Frame 073637/0222 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
Reel/Frame 073654/0300 →
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
SECURITY AGREEMENT (SECOND LIEN) Recorded Nov 4, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 062078/0276 →
SECURITY AGREEMENT (FIRST LIEN) Recorded Nov 4, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061882/0708 →
SECURITY AGREEMENT (SECOND LIEN) Recorded Oct 5, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061606/0468 →
SECURITY AGREEMENT (FIRST LIEN) Recorded Oct 4, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061595/0066 →
SECURITY INTEREST Recorded Jun 13, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON
Reel/Frame 060346/0705 →
SECURITY INTEREST Recorded Oct 5, 2021
From: BAUSCH & LOMB IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; DR. GERHARD MANN CHEM.-PHARM. FABRIK GMBH; TECHNOLAS PERFECT VISION GMBH
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 057821/0800 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2019
From: DOW PHARMACEUTICAL SCIENCES, INC.
To: BAUSCH HEALTH IRELAND LIMITED
Reel/Frame 049999/0818 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 3, 2019
From: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT PHARMACEUTICALS LUXEMBOURG S.À R.L.; VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA; VALEANT SP. Z O. O.
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 049672/0652 →
SECURITY INTEREST Recorded Mar 11, 2019
From: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 048556/0758 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 045444/0634 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 045444/0299 →
SECURITY INTEREST Recorded Jul 19, 2017
From: DOW PHARMACEUTICAL SCIENCES, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043046/0124 →
NOTICE OF SUCCESSION OF AGENCY Recorded Jan 9, 2015
From: GOLDMAN SACHS LENDING PARTNERS, LLC
To: BARCLAYS BANK PLC, AS SUCCESSOR AGENT
Reel/Frame 034749/0689 →
SECURITY AGREEMENT Recorded Jul 18, 2011
From: VALEANT PHARMACEUTICALS INTERNATIONAL, A DELAWARE CORPORATION; ATON PHARMA, INC., A DELAWARE CORPORATION; CORIA LABORATORIES, LTD., A DELAWARE CORPORATION; DOW PHARMACEUTICAL SCIENCES, INC., A DELAWARE CORPORATION; VALEANT PHARMACEUTICALS NORTH AMERICA LLC, A DELAWARE LLC; PRESTWICK PHARMACEUTICALS, INC., A DELAWARE CORPORATION; VALEANT BIOMEDICALS, INC., A DELAWARE CORPORATION
To: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT
Reel/Frame 026606/0061 →
PATENT SECURITY RELEASE AGREEMENT Recorded Mar 14, 2011
From: GOLDMAN SACHS LENDING PARTNERS LLC
To: VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS NORTH AMERICA; CORIA LABORATORIES, LTD.; DOW PHARMACEUTICAL SCIENCES, INC.; ATON PHARMA, INC.
Reel/Frame 025950/0048 →
SECURITY AGREEMENT Recorded Oct 4, 2010
From: ATON PHARMA, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA; VALEANT PHARMACEUTICALS INTERNATIONAL; CORIA LABORATORIES, LTD.; DOW PHARMACEUTICAL SCIENCES, INC.
To: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT
Reel/Frame 025084/0169 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 22, 2009
From: CHANG, YUNIK; DOW, GORDON J.
To: DOW PHARMACEUTICAL SCIENCES, INC.
Reel/Frame 022860/0320 →